Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has announced the appointment of Kyle Steiger to the role of senior vice-president and chief commercial officer (CCO).
The company noted that Steiger is a pharmaceutical industry veteran whose work experience includes specialty pharma, biologics, primary care, medical devices, over-the-counter, health policy and market access. He spent nearly 20 years at Novartis Canada in various executive positions including franchise head of hematology, vice-president of primary care and most recently vice-president of ophthalmology.
Valeo Pharma CEO Steve Saviuk said the company is pleased to add Steiger to their management team.
READ: Valeo Pharma secures loan from Sagard Healthcare Partners to fund acquisitions of pharmaceutical therapies
"He has extensive experience in our core therapeutic areas of focus, respiratory and ophthalmology, and his integrity, passion and entrepreneurial spirit are a great fit with Valeo's culture," Saviuk said in a statement.
"The recent addition of ophthalmic therapies XIIDRA and SIMBRINZA, as well as ALLERJECT for severe allergic reactions, doubles our existing revenue base. Within our broad product portfolio, we now have six drugs expected to produce significant revenue growth across three therapeutic business units, respiratory/allergy, ophthalmology, and hospital specialty. Creating the new position of CCO allows us to streamline and focus our commercial strategy and activities," Saviuk added.
Steiger said Valeo Pharma has all the right components in place to become one of the leading Canadian pharmaceutical companies.
“We have the right set of innovative products, the right team of people and appropriate corporate structure to deliver on our ambitious corporate objectives. I am thrilled to be joining the company at such an exciting time and look forward to help accelerating our growth, profitability, and industry leadership ambitions," said Steiger.
Valeo also announced that Jean-Francois Fournier has joined as its new business unit head for the ophthalmology section. Prior to joining Valeo Pharma, he served as commercial director of marketing and sales at Novartis Canada.
"Jean-Francois has a strong background in Ophthalmology and an in-depth knowledge of both XIIDRA and SIMBRINZA. We are pleased to have him assume the leadership of our new ophthalmology business unit," said Saviuk.
Kirkland, Quebec-based Valeo Pharma is a pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on respirology/allergy, ophthalmology and other products.
Contact the author at susie@proactiveinvestors.com